GlassScriptPhysician profile
Sajjad A Malick
NPI 1396709010
$2,240.52
in general payments reported to CMS, 2019-2025
23 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $297 · 2021: $1,071 · 2022: $15.66 · 2023: $35.08 · 2024: $305 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $509.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $265.42 | 2021-2025 | Talvey, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $245.07 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $179.39 | 2020-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Glaxosmithkline, LLC. | $178.43 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Celgene Corporation | $143.95 | 2019-2025 | Opdivo |
| Incyte Corporation | $138.23 | 2019-2024 | Monjuvi |
| Genentech USA, INC. | $125.31 | 2020 | |
| Daiichi Sankyo INC. | $125.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2020 | |
| Eisai INC. | $120.00 | 2024 | |
| Lilly USA, LLC | $99.99 | 2021 | |
| Seagen INC. | $91.53 | 2021 | |
| Puma Biotechnology, INC. | $79.05 | 2021 | |
| Gilead Sciences, INC. | $73.43 | 2024-2025 | Trodelvy |
| Sun Pharmaceutical Industries INC. | $61.66 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $54.35 | 2019-2020 | |
| Octapharma USA, INC. | $26.38 | 2019 | |
| Myriad Genetic Laboratories, INC. | $23.49 | 2021 | |
| Array Biopharma INC | $21.54 | 2024 | Mektovi, Lorbrena, Braftovi |
| Roche Diagnostics Corporation | $19.82 | 2020 | |
| Sirtex Medical INC | $17.55 | 2019 | |
| Amgen INC. | $13.08 | 2023 | Lumakras |
| Heron Therapeutics, INC. | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajjad Malick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.